Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib

Nakano,Yuta; Isobe,Kazutoshi; Yoshizawa,Takahiro; Urabe,Naohisa; Homma,Sakae; Kishi,Kazuma

doi:10.3892/ol.2023.13966

Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib

Authors:
- Yuta Nakano
- Kazutoshi Isobe
- Takahiro Yoshizawa
- Naohisa Urabe
- Sakae Homma
- Kazuma Kishi
View Affiliations

Affiliations: Department of Respiratory Medicine, Toho University School of Medicine, Tokyo 143‑8541, Japan
Published online on: July 20, 2023 https://doi.org/10.3892/ol.2023.13966
Article Number: 380
Copyright: © Nakano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long non‑coding RNA (lncRNA) LINC00460 is involved in tumor growth, metastasis and drug resistance. The present study investigated the clinical significance of LINC00460 expression in patients with epidermal growth factor receptor (EGFR) mutation‑positive lung cancer treated with osimertinib. Osimertinib‑resistant cells we derived from EGFR‑mutant non‑small‑cell lung cancer (NSCLC) cell lines, after which, small interfering RNA (siRNA)‑mediated silencing and in vitro‑transcribed (IVT), synthetic LINC00460 RNA transfection were used to investigate the effects of LINC00460 expression on acquired resistance to osimertinib. Reverse transcription‑quantitative polymerase chain reaction was performed to evaluate LINC00460 expression in 54 samples (RNA extracted from the tumor tissues of 30 cases and cell‑free RNA from 24 cases) obtained from patients with EGFR mutation‑positive lung cancer who had received osimertinib as the initial treatment. The acquisition of osimertinib resistance increased the expression of LINC00460 in the EGFR‑mutant NSCLC cell lines. By contrast, knockdown of LINC00460 in osimertinib‑resistant cell lines increased their sensitivity to osimertinib, whereas treatment of NSCLC cells with IVT LINC00460 RNA decreased their sensitivity to osimertinib. The present study examined LINC00460 expression at the primary tumor site and demonstrated that compared with in the low‑expression group (n=24), the high‑expression group (n=6) had a significantly lower best overall response rate to osimertinib (16.6% vs. 60.0%; P=0.044), significantly shorter median progression‑free survival (PFS; 224 days vs. 669 days; P=0.001) and significantly shorter median overall survival (724 days vs. not reached; P=0.011). Moreover, following osimertinib therapy, PFS was significantly shorter for patients with high LINC00460 expression in plasma cell‑free RNA (n=12) than for those with low LINC00460 expression (n=12) (median PFS: 655 days vs. 210 days; P=0.020). In conclusion, the upregulation of LINC00460, the expression of which is implicated in osimertinib resistance, in the primary site and plasma of patients with EGFR mutation‑positive lung cancer may be associated with a poor prognosis in those treated with osimertinib.

View Figures

View References

1	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
2	Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
4	Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
5	Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
7	Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50. 2020. View Article : Google Scholar : PubMed/NCBI
8	Pan J, Cai X, Cao Z, Pan J and Zheng H: Osimertinib in the treatment of EGFR mutation-positive advanced non-small cell lung cancer: A meta-analysis. Pharmacology. 108:8–16. 2023. View Article : Google Scholar : PubMed/NCBI
9	Tsukita Y and Inoue A: First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: A consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Jpn J Clin Oncol. 2022. View Article : Google Scholar : PubMed/NCBI
10	Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, et al: Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 24:6195–6203. 2018. View Article : Google Scholar : PubMed/NCBI
11	Piotrowska Z and Sequist LV: Tackling the next generation of resistance in EGFR-mutant lung cancer. J Thorac Oncol. 12:419–421. 2017. View Article : Google Scholar : PubMed/NCBI
12	Schoenfeld AJ, Chan JM, Kubota D, Sato H, Rizvi H, Daneshbod Y, Chang JC, Paik PK, Offin M, Arcila ME, et al: Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 26:2654–2663. 2020. View Article : Google Scholar : PubMed/NCBI
13	Yu P, He X, Lu F, Li L, Song H and Bian X: Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review. J Thorac Dis. 14:3016–3029. 2022. View Article : Google Scholar : PubMed/NCBI
14	Chen X, Song J, Wang X, Sun D, Liu Y and Jiang Y: LncRNA LINC00460: Function and mechanism in human cancer. Thorac Cancer. 13:3–14. 2022. View Article : Google Scholar : PubMed/NCBI
15	Wang HX, Kang LJ, Qin X, Xu J and Fei JW: LINC00460 promotes proliferation and inhibits apoptosis of non-small cell lung cancer cells through targeted regulation of miR-539. Eur Rev Med Pharmacol Sci. 24:6752–6758. 2020.PubMed/NCBI
16	Zhao H, Wang Y and Ren X: Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. Biosci Rep. 39:2019. View Article : Google Scholar
17	Yue QY and Zhang Y: Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 22:1003–1010. 2018.PubMed/NCBI
18	Li K, Sun D, Gou Q, Ke X, Gong Y, Zuo Y, Zhou JK, Guo C, Xia Z, Liu L, et al: Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Cancer Lett. 420:80–90. 2018. View Article : Google Scholar : PubMed/NCBI
19	Ma G, Zhu J, Liu F and Yang Y: Long noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p. DNA Cell Biol. 38:176–183. 2019. View Article : Google Scholar : PubMed/NCBI
20	Nakano Y, Isobe K, Kobayashi H, Kaburaki K, Isshiki T, Sakamoto S, Takai Y, Tochigi N, Mikami T, Iyoda A, et al: Clinical importance of long non-coding RNA LINC00460 expression in EGFR-mutant lung adenocarcinoma. Int J Oncol. 56:243–257. 2020.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Yao J, Gao R, Luo M, Li D, Guo L, Yu Z, Xiong F, Wei C, Wu B, Xu Z, et al: Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell-mediated cytotoxicity and PD-1 checkpoint. Cancer Cell Int. 22:3902022. View Article : Google Scholar : PubMed/NCBI
23	Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW and Wakelee HA: Impact of tumor suppressor gene co-mutations on differential response to EGFR TKI Therapy in EGFR L858R and exon 19 deletion lung cancer. Clin Lung Cancer. 23:264–272. 2022. View Article : Google Scholar : PubMed/NCBI
24	Gilboa T, Garden PM and Cohen L: Single-molecule analysis of nucleic acid biomarkers - A review. Anal Chim Acta. 1115:61–85. 2020. View Article : Google Scholar : PubMed/NCBI
25	Crooke ST, Witztum JL, Bennett CF and Baker BF: RNA-targeted therapeutics. Cell Metab. 27:714–739. 2018. View Article : Google Scholar : PubMed/NCBI
26	Tasaki Y, Suzuki M, Katsushima K, Shinjo K, Iijima K, Murofushi Y, Naiki-Ito A, Hayashi K, Qiu C, Takahashi A, et al: Cancer-specific targeting of taurine-upregulated gene 1 enhances the effects of chemotherapy in pancreatic cancer. Cancer Res. 81:1654–1666. 2021. View Article : Google Scholar : PubMed/NCBI